Last updated 15.09.2026
The NCG is actively involved in research related to the development and validation of innovative diagnostic methods, especially in next-generation sequencing (NGS) and bioinformatics for the identification of genetic variants associated with rare diseases and cancer.
Current research includes validation of gene panels for hereditary cancer predispositions, and participation in multicenter studies on rare genetic syndromes.
The NCG has a permanent collaboration with LIH (Luxembourg Institute of Health), contributes to scientific publications and promotes translational research in collaboration with the University of Luxembourg and international partners.
Example of projects:
Participation via Clinical Genetics for the diagnosis and follow-up of patients with rare congenital anomalies and intellectual disabilities.
More information on https://ern-ithaca.eu/
Collaboration in the development and validation of genomic screening tools to reduce time-to-diagnosis for rare diseases.
More information on https://www.screen4care.eu/
